Citi GPS Predicts $29 Billion Market For Ocular Drug Delivery System
A next generation of implantable eye treatments could change the way we treat eye conditions. And, according to a new report by Citi GPS, this experimental way to deliver eye care could turn into a $29 billion market by 2030, up from $16 billion in 2016. With the implantable method, drugs can be delivered through depots kept in the eye.
“A new wave of technologies is leveraging the eye as a natural, self-contained drug delivery chamber,” Citi biotech analyst Yigal Nochomovitz wrote in the report.
Eye diseases are becoming increasingly common, he noted, with about 34 million people being affected by either glaucoma, retinal diseases, or dry eye by 2050.
Right now, if you have a eye condition, you likely treat it with eye drops, pills that you swallow, or an injections that are put into the eye. Right now, some of the best-selling drugs are delivered via injection, such as Eyelea and Lucentis, drugs that treat macular degeneration that the US government alone spent $20 billion on in 2013.
Companies are now exploring what it would be like to implant a device into the eye that would release similar
drugs without the need for painful injections.This isn’t going to be a two-to-three year plan, Nochomovitz said in a report. But, in about a decade, there could be some shifts toward these implantable technologies as the preferred way to treat eye diseases.
